Primary Care: 24 (b)

STANDARD OPERATING PROCEDURE DOCUMENT (SOP)

Title		Influenza Outbreak in Care Homes	Doc. No.	OP233 / CL073				
Scope		Operational and clinical teams						
Guidelines		Public Health England assess and declare outbreak in a care home -> contact relevant CCG If CCG notify PC24 of need for 'Flu Treatment Plan' to be activated						
PRO	CEDURE		RESPONSIBILITY					
1		ice Manager and Manager on Call (if OOHs) will be notified of ak in care home.	CCG					
2	• R ho fo Aire Si si	 IUC Service Manager/Manager on call (if OOHs) will contact the Care Hoime to ascertain number of current residents Reassure home that PC24 we will contract within 48 hours. If a resident becomes more unwell during that time, follow usual processes (Own GP/111) Advise care home to start to compile a list of symptomatic residents Advise care home to start to compile eGFR results for all residents Source GP/ANP to contact care home within 48 hours – supported by the Shift Manager/Rota Team Inform care home of name and time of allocated clinician 						
3	 PI af Th Pi th er It 	ease note this pathway applies to <u>ALL</u> residents of the fected care home, whether or not they have been vaccinated. The pathway only applies to <u>RESIDENTS</u> in care homes. The rophylaxis for staff should be arranged via their own GP, the ough not usually needed the is a remote consultation and there is no requirement to the home is <u>ESSENTIAL</u> that the clinician assess the patients' eGFR iter to prescribing treatment, and adjust the dose as below. If	PC24 Clinician					



	eGFR is not available, ask Care Home to arrange via patients own GP. Once available, contact PC24	
4	Send prescription via EPS to nominated pharmacy ensuring SLS is visible on the script	GP/ANP
5	If during the OOHs period Shift Manager to record start and end time of clinician within the Shift Managers' report.	Shift Manager

STANDARD OPERATING PROCEDURE DOCUMENT (SOP)

Title Influenza Outbi			nza Outb	reak in Care Homes			Doc. No.	OP233 / CL073	
Version					V5				
Supersedes					V4				
Approving Managers/Committee				!	Head of Service/Head of Medicines Management				
Date Ratified					December 2017				
Departme	ent of C	Originate	or		Integrated Urgent Care				
Responsi	ble Ex	ecutive	Director		Medical Director				
Responsi	ble Ma	nager/S	Support		Head of Service				
Date Issu	ed				October 2020				
Next Revi	ew Da	ite			October 2021				
Target Audience					Clinical and Operational teams				
Version	Date		Control Reason Po			Accountable Person for this Version			
1	Dece 2017	ember	Created	Created			Head of Service		
2	Janu 2018		Updated and reviewed as required				Head of Service		
3	Octo		Update	Updated and reviewed as required				Head of Service	
4	Dece 2019	ember	Update	d and			Deputy Director of Urgent Care		
5	Octo		Updated and reviewed as required				Head of Service		
Reference documents					Electronic Locations	Location	ns for Hard Copies		
Coi				Cor	ent Care 24 Intranet / porate Policies/ Current PS/	Standard Operating Procedures File in the Call Centre.		e Call	
Document Status: This is a controlled document. Whilst this document may be printed, the electronic version maintained on the UC24 Intranet is the controlled copy. Any printed copies of the document are not controlled.									

Appendix A - Clinical Pathway

	Creatinine Clearance (eGFR)	Testing Time	Oseltamivir (Tamiflu®) dose		
CKD Stages			Prophylaxis	Treatment	
Stage 1	>90 ml/min	Annual	75mg once per day for 10 days	75mg twice daily for 5 days	
Stage 2	60-89 ml/min	Annual	75mg once per day for 10 days	75mg twice daily for 5 days	
Stage 3	30-59 ml/min	Annual (known to be stable) 6-monthly (progressive)	30 mg once per day for 10 days	30 mg twice daily for 5 days	
Stage 4	15-29 ml/min	6-monthly (stable) 3-monthly (progressive)	30mg every 48hrs for 10 days	30 mg once per day for 5 days	
**Stage 5	<15 ml/min	monthly	Seek specialist advice.	Seek specialist advice.	

^{*} Source BNF, NICE CKD Guidance 2014, Mersey Renal Units http://www.merseyrenalunits.nhs.uk/proforma/managementofckd/measureserum.asp